CareDx moves into oncology with planned Naveris acquisition

Version 1 — Brief

CareDx said on April 29, 2026, that it has agreed to acquire Naveris in a deal valued at up to about $260 million, made up of $160 million in upfront cash and as much as $100 million tied to revenue milestones. Naveris is a commercial-stage oncology diagnostics company best known for NavDx, a blood-based test that detects tumor tissue-modified viral HPV DNA for post-treatment surveillance and molecular residual disease monitoring in HPV-driven cancers. CareDx said Naveris generated an estimated $34 million in unaudited 2025 revenue, with first-quarter 2026 revenue of about $12 million, and framed the deal as an expansion from transplant diagnostics into specialty oncology. (biospace.com)

Why it matters: For veterinary professionals, this is less about the human oncology asset itself and more about where diagnostics capital is moving. The deal shows continued investor and strategic interest in repeat-use, blood-based monitoring platforms with reimbursement in place, a model that has parallels across animal health diagnostics. Naveris already has Medicare coverage for NavDx in HPV-driven head and neck cancer, and it expanded Medicare coverage in late 2025 for anal squamous cell carcinoma surveillance, which likely made the asset more attractive to buyers looking for reimbursed, clinically validated testing businesses. (naveris.com)

What to watch: Watch for closing timing, any updated CareDx guidance after the deal closes, and whether the company uses Naveris’ platform to push beyond its current HPV-focused indications. (biospace.com)